trial

One-Year Trial Of Oral Ziprasidone In Patients With Metabolic Syndrome

NCTId NCT00748566
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Terminated
Enrollment 172 (actual)
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Primary completion 2012-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Terminated
Enrollment
172 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Single Group
Masking
None
Start
2008-12
Primary completion
2012-05
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Ziprasidone

Sponsors

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Lead Sponsor

Sites

32 total
Calgary, CanadaCalgary, CanadaMedicine Hat, CanadaMedicine Hat, CanadaRed Deer, CanadaPenticton, CanadaVictoria, CanadaWinnipeg, CanadaWinnipeg, CanadaWinnipeg, CanadaWinnipeg, CanadaBathurst, Canada

Facts & assertions

4 sourced
Enrollment
172
Phase
PHASE4
Primary Completion Date
2012-05
Status
TERMINATED
relationships
The graph out of here
drug
Ziprasidone
drug
lead_sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
company
indication
Schizophrenia Spectrum and Other Psychotic Disorders
indication
Metabolic Syndrome
indication
Psychotic Disorders
indication